Tags: Anxiety | High Blood Pressure | brintellix | antidepressant | depression | drug | lundbeck

New Antidepressant Brintellix OKd

Tuesday, 01 Oct 2013 11:29 AM

The U.S. Food and Drug Administration approved Lundbeck's antidepressant Brintellix to treat adults with major depressive disorder.

The drug, which Lundbeck will co-market with Japanese partner Takeda Pharmaceutical Co Ltd, will be available in four doses.
 
Brintellix, like other antidepressants, will carry a boxed warning alerting patients and doctors to an increased risk of suicidal thoughts and behavior in children, adolescents and young adults aged 18-24 during initial treatment.
 
The most common side effects reported by patients taking the drug — generically known as vortioxetine — include nausea, constipation and vomiting.

Major depressive disorder is characterized by mood changes that may interfere with a person's ability to carry out to day-to-day activities. Symptoms also include increased fatigue and feelings of guilt or worthlessness.

© 2015 Thomson/Reuters. All rights reserved.

1Like our page
2Share
FDA-Approved-Drugs
TheU.S. Food and Drug Administration approved Lundbeck's antidepressant Brintellix to treat adults with major depressive disorder. The drug, which Lundbeck will co-market with Japanese partner Takeda Pharmaceutical Co Ltd, will be available in four doses. Brintellix,like...
brintellix,antidepressant,depression,drug,lundbeck
121
2013-29-01
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved